Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
about
Fibrates for secondary prevention of cardiovascular disease and strokeLipid abnormalities in kidney disease and management strategiesRenal failure (chronic)Dyslipidemia associated with chronic kidney diseaseEffect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.High density lipoprotein and cardiovascular diseases.Kidney function and estimated vascular risk in patients with primary dyslipidemiaMechanisms for increased cardiovascular disease in chronic kidney dysfunction.Renal dysfunction potentiates foam cell formation by repressing ABCA1.High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.Role of dyslipidemia in patients with chronic kidney disease.HDL abnormalities in nephrotic syndrome and chronic kidney disease.Triglyceride Treatment in the Age of Cholesterol Reduction.Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.Different effects of low weight molecular heparin and unfractioned heparin on lipid profile and coagulation at haemodialysis patients.The lipid story in chronic kidney disease: a long story with a happy end?
P2860
Q24186376-52EA1A41-7286-4D57-9F29-0CCE4F02FC66Q27024982-07019044-1897-4FC7-A443-2E225DB7A110Q33910618-5944E11E-249C-43CD-88C5-5CCE7E5A2127Q35020237-8BC43FB6-CC7A-4271-A80E-0E6450FEFA7CQ35667598-A522C0C6-89AA-4D53-899F-02C5A2FCAD4CQ35691372-616AF154-3CB4-4E80-85D5-90C96430A8B3Q37043222-8553EFAA-D746-498A-9B2A-6707F0281054Q37245464-6D2E45FB-1BA5-402A-A42A-0C1ADB467412Q37289195-4AF813CA-2E7C-4DAB-A865-EB1792D552DAQ37357219-EFE16226-02FE-49C0-AAC2-8DAD15141F22Q38084913-803FF4CA-4544-4922-8E3C-D624EDDCBBFFQ38120646-91AB26D5-796D-4441-96A1-604E4CA45AA4Q38633497-AFAD5E52-E90B-48FF-9672-FF461EA8ED29Q38932760-15AB212B-A23C-45AF-85E0-6534C0CE6ADBQ39826326-26C9E500-0E9D-4EBE-B3E3-D3FA90999C83Q42280566-A48021EE-069B-4EE8-A942-0368A4D0C57AQ42912193-EE4BB2B3-E7CD-4573-B107-E34689B0E74B
P2860
Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Gemfibrozil for secondary prev ...... e chronic renal insufficiency.
@en
Gemfibrozil for secondary prev ...... e chronic renal insufficiency.
@nl
type
label
Gemfibrozil for secondary prev ...... e chronic renal insufficiency.
@en
Gemfibrozil for secondary prev ...... e chronic renal insufficiency.
@nl
prefLabel
Gemfibrozil for secondary prev ...... e chronic renal insufficiency.
@en
Gemfibrozil for secondary prev ...... e chronic renal insufficiency.
@nl
P2093
P50
P1433
P1476
Gemfibrozil for secondary prev ...... e chronic renal insufficiency.
@en
P2093
Dorothea Collins
Gary C Curhan
Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators
P304
P356
10.1111/J.1523-1755.2004.00862.X
P407
P577
2004-09-01T00:00:00Z
P5875
P6179
1018064004